Currently out of the existing stock ratings of Bradley Canino, 99 are a BUY (81.15%), 23 are a HOLD (18.85%).

Bradley Canino

Work Performance Price Targets & Ratings Chart

Analyst Bradley Canino, currently employed at STIFEL, carries an average stock price target met ratio of 40.55% that have a potential upside of 46.46% achieved within 136 days. Previously, Bradley Canino worked at GUGGENHEIM.

Bradley Canino’s has documented 241 price targets and ratings displayed on 20 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on CELC, Celcuity LLC at 21-Sep-2025.

Wall Street Analyst Bradley Canino

Analyst best performing recommendations are on SMMT (SUMMIT THERAPEUTICS PLC).
The best stock recommendation documented was for SMMT (SUMMIT THERAPEUTICS PLC) at 9/9/2024. The price target of $25 was fulfilled within 3 days with a profit of $5.86 (30.62%) receiving and performance score of 102.06.

Average potential price target upside

of $28.49 (47.17%) on BPMC (BLUEPRINT MEDICINES CORP).
of $28.47 (185.27%) on ARVN (ARVINAS).
of $24.33 (153.88%) on CELC (CELCUITY LLC).

ALXO Alx Oncology Holdings ARVN Arvinas BPMC Blueprint Medicines Corp CCCC C4 Therapeutics DCPH Deciphera Pharmaceuticals LLC TPTX Turning Point Therapeutics ZNTL Zentalis Pharmaceuticals Llc BDTX Black Diamond Therapeutics KYMR Kymera Therapeutics AFMD Affimed NV MRUS Merus BV RLAY Relay Therapeutics KURA Kura Oncology SNDX Syndax Pharmaceuticals THRX Theseus Pharmaceuticals NUVL Nuvalent CELC Celcuity LLC JANX Janux Therapeutics SMMT Summit Therapeutics PLC CGEM Cullinan Oncology LLC

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Colin Bristow (UBS)